Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib maintenance versus placebo in epithelial ovarian, fallopian tube, or primary peritoneal cancer after first-line chemotherapy
2008-004672-50Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Pazopanib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
pazopanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-004672-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004672-50.